Ayurcann Holdings Corp. a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has entered into a patient-referral agreement with The Herb Clinic providing Canadians guidance and access to managing discomfort with medicinal cannabis. The Herb Clinic has over 4000 patients registered and is ...

Ayurcann Holdings Corp. (CSE: AYUR) (FSE:3ZQ0) (the " Company " or " Ayurcann ") a Canadian cannabis extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to announce that it has entered into a patient-referral agreement with The Herb Clinic (" Clinic "), providing Canadians guidance and access to managing discomfort with medicinal cannabis.

The Herb Clinic has over 4000 patients registered and is comprised of compassionate and knowledgeable service providers who are defined by their ability to provide exceptional patient care. They help educate and integrate cannabis into the patient's medical treatment plans and partner with medicinal cannabis providers such as Ayurcann, to ensure their patients are getting top-quality advice with exceptional value.

The terms of the agreement will see The Herb Clinic send medical cannabis patients to Ayurcann through a patient education agreement. Ayurcann will work with the patients to educate them on their available offerings and help them select appropriate products.

A Media Snippet accompanying this announcement is available by clicking on the image or link below :

"Working with the leaders in the industry is what we strive towards, being able to partner with and enhance cannabis education, provide the best possible value, national coverage, while expending our offerings for the best national and international brands for THC and CBD based products to patients is making Ayurcann and Ayurcann marketplace a leader in the industry," commented Igal Sudman, CEO of Ayurcann.

For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322
Email: infol@Ayurcann.com

Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: ir@Ayurcann.com

About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company's expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company's facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company's business, financial condition and/or results of operations.  The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Greenrose Acquisition Corp. - GNRS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Greenrose Acquisition Corp. - GNRS

Pomerantz LLP is investigating claims on behalf of investors of Greenrose Acquisition Corp. ("Greenrose" or the "Company") (OTCMKTS: GNRS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Greenrose and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Keep reading... Show less
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Greenrose Acquisition Corp.  Investigation

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Greenrose Acquisition Corp. Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Greenrose Acquisition Corp. ("Greenrose" or the "Company") (OTCMKTS:GNRS). Investors who purchased Greenrose sharesare encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.comgnrs

The investigation concerns whether Greenrose and certain of its officers and/or directors have violated federal securities laws.

Keep reading... Show less

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Cronos Group Inc. with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

Keep reading... Show less

Trulieve Celebrates Grand Opening of New Tampa Dispensary

Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving patients at this location at 9:00 am on Thursday, December 2 and will continue the celebration with all-day festivities and deals. The new location is Trulieve's 110 th dispensary in Florida and its 157 th nationwide.

Keep reading... Show less
bird's-eye view of the Lift Expo 2021 show floor

Lift Expo Welcomes Cannabis Investors Back

The Canadian cannabis business sector witnessed the return of a staple in the industry with the first Lift & Co. Expo held since before the start of the COVID-19 pandemic.

It has been 29 months since the last time the Toronto Convention Center hosted a Lift cannabis event.

Shawn Pierce, president of strategic events, meetings and incentives at MCI Group, the company overseeing the branding of Lift & Co., told the Investing News Network (INN) that setting up the event again was a challenge made especially difficult living in a world that is still enduring a global pandemic.

Keep reading... Show less
Quizam Media Quantum 1 Cannabis Russ Rossi

Quantum 1 Cannabis CEO Russ Rossi: Increasing Customer Base and Eroding the Cannabis Black Market

Quantum 1 Cannabis (CSE:QQ) recently announced the grand opening of its brand-new flagship Vancouver store located at 5528 Cambie Street.

Quantum 1 Cannabis CEO Russ Rossi shared how the company's presence within the C$5 billion redevelopment project in BC is increasing its customer base and gradually eroding the cannabis black market.

Keep reading... Show less

Top News

Related News